|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||
| Current Assets: | ||||||||||||||||||
| Cash | ||||||||||||||||||
| Total cash | ||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||
| Total prepaid expenses and other current assets | ||||||||||||||||||
| Vendor deposits | ||||||||||||||||||
| Total vendor deposits | ||||||||||||||||||
| Total Current Assets | ||||||||||||||||||
| Equipment, net | ||||||||||||||||||
| Total equipment, net | ||||||||||||||||||
| In-process research and development | ||||||||||||||||||
| Total in-process research and development | ||||||||||||||||||
| In-process research and development | ||||||||||||||||||
| Goodwill | ||||||||||||||||||
| Security deposit | ||||||||||||||||||
| Total security deposit | ||||||||||||||||||
| Vendor deposit | ||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||
| Total Assets | ||||||||||||||||||
| Liabilities and Stockholders’ Deficit | ||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||
| Accounts payable | ||||||||||||||||||
| Total accounts payable | ||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||
| Total accrued expenses and other current liabilities | ||||||||||||||||||
| Operating lease liability | ||||||||||||||||||
| Convertible notes payable at fair value | ||||||||||||||||||
| Total convertible notes payable at fair value | ||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||
| Liabilities | ||||||||||||||||||
| Total Liabilities | ||||||||||||||||||
| Stockholders’ Deficit: | ||||||||||||||||||
| Preferred stock | ||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||
| Total preferred stock | ||||||||||||||||||
| Common stock | ||||||||||||||||||
| Total common stock | ||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||
| Total additional paid-in-capital | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| Total accumulated deficit | ||||||||||||||||||
| Treasury stock, at cost, 7 shares at March 31, 2026 and December 31, 2025 | ||||||||||||||||||
| Total Stockholders’ Deficit | ||||||||||||||||||
| Total Liabilities and Stockholders’ Deficit | ||||||||||||||||||
Loading...